Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Venetoclax and Hypomethylating Agents Confirmed to be Standard Therapy in De Novo and ELN17 Not Adverse Acute Myeloid Leukemia Patients, Unfit for Chemotherapy According to SIE/Sies/GITMO Criteria. a Multicentric Real-Life Study on 379 Patients, By the Hematological Network Rete Ematologica Lombarda (REL)

Blood (2024) 144 (Supplement 1): 2863.

https://doi.org/10.1182/blood-2024-202530

Published: 2024

Journal Articles

Disease Course and Treatment Patterns of Acute Myeloid Leukemia with FLT3 Mutations and Myeloid Sarcoma Reveal High Efficacy of Gilteritinib: A Multicentric Retrospective Study

Francesco Angotzi, Erika Borlenghi, Chiara Sartor, Maria Benedetta Giannini, Giovanni Marconi, Edoardo Tamellini, Mauro Turrini, Federica Loscocco, Ernesta Audisio, Vincenzo Federico, Calogero Vetro, Andrea Visentin, Carmela Gurrieri, Livio Trentin, Felicetto Ferrara, Federica Lessi

Blood (2024) 144 (Supplement 1): 1523.

https://doi.org/10.1182/blood-2024-209605

Published: 2024

Journal Articles

Italian Real-World Experience of Gilteritinib Monotherapy in Patients with Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: Preliminary Results

Blood (2024) 144 (Supplement 1): 5188.

https://doi.org/10.1182/blood-2024-205427

Published: 2024

Journal Articles

Myelodysplastic Neoplasms Patients' and Caregivers' Unmet Needs and Their Impact on Their Quality of Life and Symptoms

Blood (2024) 144 (Supplement 1): 3800.

https://doi.org/10.1182/blood-2024-210768

Published: 2024

Journal Articles

Multiparametric Flow Cytometry-MRD Assay: Lesson from Phase II Trail REL AML 001

Blood (2023) 142 (Supplement 1): 5997.

https://doi.org/10.1182/blood-2023-185555

Published: 2023

Journal Articles

Efficacy and Safety of Luspatercept in Adult Patients with Transfusion-Dependent Anemia Due to Very Low, Low and Intermediate Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts, Who Had an Unsatisfactory Response to or Are Ineligible for Erythropoietin-Based Therapy: A Retrospective Multicenter Study By Fondazione Italiana Sindromi Mielodisplastiche (FiSiM ETS)

Luca Lanino, Prassede Salutari, Alessandra Perego, Bruno Fattizzo, Marta Riva, Marta Ubezio, Pellegrino Musto, Daniela Cilloni, Esther Natalie Oliva, Maria Teresa Voso, Anna Maria Pelizzari, Antonella Poloni, Isabella Capodanno, Chiara Elena, Claudio Fozza, Fabrizio Pane, Massimo Breccia, Marco De Gobbi, Francesco Di Bassiano, Daniela Barraco, Elena Crisà, Dario Ferrero, Chiara Frairia, Antonella Vaccarino, Davide Griguolo, Stefania Paolini, Martina Quintini, Mariarosaria Sessa, Mauro Turrini, Monica Bocchia, Nicola Di Renzo, Elisa Diral, Cristina Foli, Alfredo Molteni, Ubaldo Occhini, Giulia Rivoli, Carmine Selleri, Roberto Bono, Anna Calvisi, Andrea Castelli, Eros Di Bona, Ambra Di Veroli, Luana Fianchi, Sara Galimberti, Daniele Grimaldi, Monia Marchetti, Marianna Norata, Alessandro Rambaldi, Ilaria Tanasi, Patrizia Tosi, Ilaria Naldi, Valeria Santini, Matteo G. Della Porta

Blood (2022) 140 (Supplement 1): 6945–6948.

https://doi.org/10.1182/blood-2022-164559

Published: 2022

Journal Articles

Evolutionary Portrait of Adult Core-Binding Factor Leukemia Patients Treated with a Continuation Therapy with Midostaurin: Preliminary Results

Blood (2022) 140 (Supplement 1): 9054–9056.

https://doi.org/10.1182/blood-2022-160024

Published: 2022

Journal Articles

Treatment of Elderly Patients with Acute Promyelocytic Leukemia: A Real Life Experience of the "Rete Ematologica Lombarda"

Valentina Mancini, MD, Erika Borlenghi, MD, Livia Leuzzi, MD, Claudia Basilico, MD, Massimo Bernardi, MD, Patrizia Zappasodi, MD, Monica Fumagalli, MD, Elisabetta Todisco, MD PhD, Chiara Cattaneo, MD, Federico Lussana, MD, Giambattista Bertani, MD, Erika Ravelli, MD, Nicola Fracchiolla, Mauro Turrini, Giuseppe Rossi, Silvia Cantoni, Roberto Cairoli, MD

Blood (2019) 134 (Supplement_1): 3862.

https://doi.org/10.1182/blood-2019-130089

Published: 2019

Journal Articles

Progressive Down Regulation of JAK-STAT, Cell Cycle, and ABC Transporter Genes in CD34+/Lin- Cells of Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients at Diagnosis Vs. 12 Months of Nilotinib Treatment Vs. Healthy Subjects

Blood (2019) 134 (Supplement_1): 5034.

https://doi.org/10.1182/blood-2019-125595

Published: 2019

Journal Articles

Nilotinib Deregulates Cell Cycle Checkpoints, ABC Transporters Genes and JAK-STAT Signaling Pathway of CD34+/Lin- Cells in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients after 12 Months of Treatment

Blood (2018) 132 (Supplement 1): 5122.

https://doi.org/10.1182/blood-2018-99-112188

Published: 2018

Journal Articles

Combining Imatinib-Following-Nilotinib Treatment in First Line Therapy for Chronic Phase Chronic Myeloid Leukemia. Update from the PhilosoPhi34 Study at 24 Months of Follow-up

Blood (2018) 132 (Supplement 1): 5435.

https://doi.org/10.1182/blood-2018-99-113496

Published: 2018

Journal Articles

Jak-2 and Nfkbia G ene Expression Play a Strategic Role in Chronic Myeloid Leukemia (CML) Molecular Response during Early Nilotinib Treatment: The PhilosoPhi34 Data

Blood (2018) 132 (Supplement 1): 5118.

https://doi.org/10.1182/blood-2018-99-113273

Published: 2018

Journal Articles

Preliminary Experience of Imatinib after Nilotinib in the First Line Treatment of Chronic Myeloid Leukemia

Blood (2017) 130 (Supplement 1): 2889.

https://doi.org/10.1182/blood.V130.Suppl_1.2889.2889

Published: 2017

Journal Articles

Gene Expression Profiling and Cellularity of Bone Marrow CD34+/Lin- Cells of Patients with Chronic-Phase Chronic Myeloid Leukemia at Diagnosis Vs. 12 Months of First-Line Nilotinib Treatment

Blood (2017) 130 (Supplement 1): 4973.

https://doi.org/10.1182/blood.V130.Suppl_1.4973.4973

Published: 2017

Journal Articles

The REL-Protocol PhilosoPhi34 - an Open Label, Single Arm, Phase II Study of Nilotinib 300 Mg BID in Newly Diagnosed Chronic Phase Chronic Myeloid Leukaemia (CML) Patients - Confirms Early Clearance of Bone Marrow CD34+/Lin-Ph+ Cells

Blood (2016) 128 (22): 3080.

https://doi.org/10.1182/blood.V128.22.3080.3080

Published: 2016

Journal Articles

REL-Protocol PhilosoPhi34: An Open Label, Single Arm, Phase II Study of Nilotinib 300 Mg BID in Newly Diagnosed Chronic Phase Chronic Myeloid Leukaemia Patients, to Study the Disappearance of CD34+/Lin-Ph+ Cells from Bone Marrow during Treatment. Preliminary Data

Blood (2015) 126 (23): 1597.

https://doi.org/10.1182/blood.V126.23.1597.1597

Published: 2015

Journal Articles

GEP Analyses of Bone Marrow CD34+/Lin- Cells of Chronic Phase CML Patients at Diagnosis Identified Different Sets of Genes Associated to the Molecular Response after 3 and 6 Months of First-Line Nilotinib Treatment

Alessandra Trojani, PhD, Ester Pungolino, MD, Milena Lodola, Barbara Di Camillo, Mariella D'Adda, MD, Alessandra Perego, MD, Mauro Turrini, MD, Chiara Elena, MD, Alessandra Iurlo, MD PhD, Cristina Buccelli, Simona Malato, MD, Francesco Spina, MD, Maria Luisa Latargia, Francesco Lanza, Sergio Pauli, MD, Michela Anghilieri, MD, Maria Cristina Carraro, Enrica Morra, MD, Roberto Cairoli, MD

Blood (2015) 126 (23): 3645.

https://doi.org/10.1182/blood.V126.23.3645.3645

Published: 2015

Journal Articles

Characterization Of Genes and Pathways From The Comparison Between Bone Marrow B Cells As Well As Plasma Cells Of Waldenström Macroglobulinemia (WM) Vs. IgM Monoclonal Gammopathy Of Undetermined Significance (IgM-MGUS) Vs. Healthy Subjects Using Gene Profiling

Alessandra Trojani, Milena Lodola, Antonino Greco, Alessandra Tedeschi, MD, Barbara Di Camillo, Francesca Ricci, Anna Maria Frustaci, Mauro Turrini, Enrica Morra, MD

Blood (2013) 122 (21): 3772.

https://doi.org/10.1182/blood.V122.21.3772.3772

Published: 2013

Journal Articles

Microarray Identifies Different Molecular Signatures of Waldenstrom Macroglobulinemia (WM) Compared to IgM Monoclonal Gammopathy of Undetermined Significance (IgMMGUS)

Alessandra Trojani, Antonino Greco, Alessandra Tedeschi, MD, Barbara Di Camillo, Milena Lodola, Francesca Ricci, MD, Mauro Turrini, Marzia Varettoni, Sara Rattotti, Enrica Morra, MD

Blood (2012) 120 (21): 3495.

https://doi.org/10.1182/blood.V120.21.3495.3495

Published: 2012

Journal Articles

Multicentric Clinical Audit of Chemotherapy Administration for Lymphoprolipherative Diseases in Day Hospital Patient Setting

Giuliana Emilia Muti, MD, Chiara Rusconi, MD, Anna Brizio, MD, Mauro Turrini, MD, Piera Viero, MD, Carmela Iazzetta, Michela Terzi, Claudia Vener, MD, Consuelo Corti, MD, Fabio Giglio, MD, Morena Nazzari, MD, Cristina Fiamenghi, Enrica Morra, MD

Blood (2008) 112 (11): 4712.

https://doi.org/10.1182/blood.V112.11.4712.4712

Published: 2008

NARROW

Disease Course and Treatment Patterns of Acute Myeloid Leukemia with FLT3 Mutations and Myeloid Sarcoma Reveal High Efficacy of Gilteritinib: A Multicentric Retrospective Study

Italian Real-World Experience of Gilteritinib Monotherapy in Patients with Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: Preliminary Results

Myelodysplastic Neoplasms Patients' and Caregivers' Unmet Needs and Their Impact on Their Quality of Life and Symptoms

Multiparametric Flow Cytometry-MRD Assay: Lesson from Phase II Trail REL AML 001

Evolutionary Portrait of Adult Core-Binding Factor Leukemia Patients Treated with a Continuation Therapy with Midostaurin: Preliminary Results

Treatment of Elderly Patients with Acute Promyelocytic Leukemia: A Real Life Experience of the "Rete Ematologica Lombarda"

Progressive Down Regulation of JAK-STAT, Cell Cycle, and ABC Transporter Genes in CD34+/Lin- Cells of Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients at Diagnosis Vs. 12 Months of Nilotinib Treatment Vs. Healthy Subjects

Nilotinib Deregulates Cell Cycle Checkpoints, ABC Transporters Genes and JAK-STAT Signaling Pathway of CD34+/Lin- Cells in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients after 12 Months of Treatment

Combining Imatinib-Following-Nilotinib Treatment in First Line Therapy for Chronic Phase Chronic Myeloid Leukemia. Update from the PhilosoPhi34 Study at 24 Months of Follow-up

Jak-2 and Nfkbia G ene Expression Play a Strategic Role in Chronic Myeloid Leukemia (CML) Molecular Response during Early Nilotinib Treatment: The PhilosoPhi34 Data

Preliminary Experience of Imatinib after Nilotinib in the First Line Treatment of Chronic Myeloid Leukemia

Gene Expression Profiling and Cellularity of Bone Marrow CD34+/Lin- Cells of Patients with Chronic-Phase Chronic Myeloid Leukemia at Diagnosis Vs. 12 Months of First-Line Nilotinib Treatment

The REL-Protocol PhilosoPhi34 - an Open Label, Single Arm, Phase II Study of Nilotinib 300 Mg BID in Newly Diagnosed Chronic Phase Chronic Myeloid Leukaemia (CML) Patients - Confirms Early Clearance of Bone Marrow CD34+/Lin-Ph+ Cells

REL-Protocol PhilosoPhi34: An Open Label, Single Arm, Phase II Study of Nilotinib 300 Mg BID in Newly Diagnosed Chronic Phase Chronic Myeloid Leukaemia Patients, to Study the Disappearance of CD34+/Lin-Ph+ Cells from Bone Marrow during Treatment. Preliminary Data

GEP Analyses of Bone Marrow CD34+/Lin- Cells of Chronic Phase CML Patients at Diagnosis Identified Different Sets of Genes Associated to the Molecular Response after 3 and 6 Months of First-Line Nilotinib Treatment

Characterization Of Genes and Pathways From The Comparison Between Bone Marrow B Cells As Well As Plasma Cells Of Waldenström Macroglobulinemia (WM) Vs. IgM Monoclonal Gammopathy Of Undetermined Significance (IgM-MGUS) Vs. Healthy Subjects Using Gene Profiling

Microarray Identifies Different Molecular Signatures of Waldenstrom Macroglobulinemia (WM) Compared to IgM Monoclonal Gammopathy of Undetermined Significance (IgMMGUS)

Multicentric Clinical Audit of Chemotherapy Administration for Lymphoprolipherative Diseases in Day Hospital Patient Setting

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only